Abstract
Introduction
Belgium has introduced economic studies into decision-making in health care in 2002, simultaneously with a number of European countries. Originally, these studies were only focussed on pharmaceuticals, but later additional technologies such as diagnostics and implants have become subject to economic evaluations. Guidelines on how to perform economic evaluations for pharmaceuticals were finalised and adopted in 2008 and updated in 2015. 1, 2 As a consequence, a number of cost studies have been performed in Belgium to be used not only as policy support but also as the basis for economic evaluations, including in multiple sclerosis (MS). [3] [4] [5] The availability of disease-modifying treatments (DMTs) has led to changes in patient management and a focus on earlier and better diagnosis and adjustments in the diagnostic criteria themselves. One of the consequences in this regard is that the recorded prevalence of the disease is quite different from that estimated two or three decades ago. 6, 7 However, the last study for Belgium was performed in Flanders in 1994, and no updated estimates for the country are available. 8 With diagnosis already possible after a clinically isolated event, 9 one must also expect a different distribution of the type of MS and the severity of the disease compared to 10 years ago: a larger proportion of patients with relapsing-remitting multiple sclerosis (RRMS) and thus of patients in the early stages of Expanded Disability Status Scale (EDSS).
It is therefore important to update the information on the burden of MS, and the study presented here is part of a European-wide effort to update information on the burden of illness of MS in 16 countries, endorsed by the European Platform of MS Societies (EMSP) and carried out with the support of national MS societies. 10 It uses a similar methodology as the last European survey in 2005 that also included Belgium. 5, 11 Materials and methods The detailed methodology for the European survey is published separately. 12 We therefore only provide a short summary of the general methods and issues specific to Belgium.
Data
The study aimed to estimate the costs of all health care and other resource utilisation related to MS: hospitalisation, rehabilitation, consultations, diagnostic procedures and tests, medication, community care, family support and production losses (sick leave, early retirement and invalidity). In addition, information on major symptoms such as fatigue and cognitive difficulties (using visual analogue scales (VAS), health-related quality of life (HRQoL) as well as selfassessed disability using descriptions based on the EDSS) was collected.
Data were collected with a standard questionnaire, at a single point in time, for a retrospective period of time. The latter was varied depending on the question to minimise recall bias: 1 month for use of drugs, community services and family help; 3 months for hospitalisation, consultations, tests, sick leave and relapses; and 12 months for major investments. Resource utilisation is reported for these time periods, while cost calculations are annualised.
Disease information such as the type of MS, disability (EDSS), HRQoL, utility (EuroQol five-dimensions (EQ-5D) 13 ) symptoms (fatigue, cognitive difficulties) and the effect of MS on work related to the current day or week. For comparability within the European study, we calculated utility scores with the original value set developed in the United Kingdom ( Figure  4(a) ). 14 Many countries have subsequently produced their own national tariff, using the same methodology. However, in Belgium, the tariff was established with a different methodology. 15, 16 The study used the VAS included in the EQ-5D and included 722 participants in Belgium. As a consequence, the scores obtained are not comparable, but they are presented separately for information (Figure 4(b) ).
The handling of missing data for the cost calculation is explained in more detail in the paper describing the methods. 17 For resource use, we present actual answers without any imputation for missing answers. Also, no imputations are made for missing information on disease status, symptoms and HRQoL.
Costs
Costs are calculated from the societal perspective, including all costs regardless of who ultimately is responsible for them. Patient co-payments and patients' out-of-pocket expenses are thus included.
The cost of a relapse is calculated as the difference in quarterly costs between patients with or without a relapse and an EDSS score between 0 and 6; patients who were unsure about whether they had had a relapse or not were excluded from this estimation. Invalidity, early retirement and DMT costs are not considered in this calculation as they are unlikely to be affected within 3 months.
Unit costs for the individual resources were taken from public sources and are summarised in the paper on the study methods, 12 and results are reported in EUR 2015.
Patients
The objective was to include a sample where all levels of disease severity (defined by EDSS) were represented in sufficient numbers to permit analysis, rather than a prevalence sample. This highlights how costs and HRQoL change as the disease progresses and provides the necessary data for cost-effectiveness analysis of treatments that are expected to change the course of the disease. Mean results may thus not be representative and should neither be extrapolated directly to national costs nor be compared directly to the results in earlier studies. We therefore report results by disease severity groups only (mild MS, EDSS 0-3; moderate MS, EDSS 4-6.5; severe MS, EDSS 7-9).
Data collection
In anonymous surveys, participation will depend heavily on the methods used for the survey: collecting data in MS centres tends to overestimate the number of patients with early disease and on treatment with DMTs; collecting data from members of patient organisations may lead to a bias towards patients with long-standing disease. Internet surveys will bias towards younger patients with better education, while postal surveys may bias towards older patients.
The Belgian participants were members of the bi-lingual national MS society (Ligue Nationale Belge de la Sclérose en Plaques/Nationale Belgische MS Liga). The MS society invited 6500 individuals by direct postal mail (French-speaking part) or together with the postal quarterly news bulletin (Flemish-speaking part), and the response rate reached 29%. The data were collected during the spring of 2015.
Results
A total of 1856 evaluable responses were received, 89% on paper, which led to a certain number of missing data. The geographical distribution of respondents represented very closely the inhabitants of the different regions. Table 1 provides details on demographics, employment and disease.
Demographics and employment
The age of respondents in Belgium ranged from 18 to 95 years (mean: 54.0, median: 54, standard deviation (SD) = 12.6). Women represented 70% of the sample; 73% lived with their family, and the high age of some participants explains that 50 patients lived in a nursing home at the time of the survey. Education levels in our sample were comparable to the general population of that age group: 17% of the patients had basic education, 44% had a secondary or a professional degree and 35% had a university degree. This compares to 29%, 37% and 35% in the general population in 2011. 18 Despite the relatively high mean age, a majority of patients in the sample (1217 patients, 66%) were below retirement age (defined as the average effective retirement age, 58.7 for women and 59.7 for men 19 ). Of these, 538 patients (44%) patients were employed or self-employed. In all, 22 patients above retirement age also worked, bringing this group to 560 patients (or 30% of the full sample), with a mean age of 45.9 years. This compares to an employment rate of 62.2% in the general population aged 16-64 years. 20 The majority of patients worked part-time (73%), and of these, 21% did so because of MS. In the general population, 27% of people work part-time, illustrating again how much MS affects patients' activities. 20 Average working hours in the sample were 38.5 hours for full-time workers and 22.6 hours for part-time employees. Sick leave during the past 3 months was reported by a quarter of working patients (n = 141), with a mean duration of 17.1 days. This may be mostly due to relapses that were reported by 299 patients (16%).
Employment decreased rapidly with advancing disease, as shown in Figure 1 . Of non-employed patients, 57% indicated MS as the reason.
Most employed patients felt that MS affected their productivity at work (85%) and only 6% indicated that they had no problems, while 9% had not answered the question. The severity of the effect covered the entire VAS range from 0 to 10, with a mean of 4.5 (SD = 2.7) (Figure 2 ). Fatigue was considered the most bothersome symptom (83%), followed by difficulties in thinking (37%), pain (32%), mobility (27%) and low mood (16%).
Disease characteristics
Disease information is summarised in Table 1 . The mean EDSS in the sample was 4.6 (SD = 2.5), with 64% of the patients at EDSS 6 or higher. This makes it the most severe sample in the European study. However, the number of patients at all levels of EDSS was sufficient to yield a stable analysis, with the exception of EDSS 9 (10 patients only). The mild group represented 18% of the sample, the moderate group 51% and the severe group 31%.
The proportion of patients with RRMS was 43%, with secondary progressive multiple sclerosis (SPMS) reported at 24% and with primary progressive multiple sclerosis (PPMS) reported at 22% (10% missing). The proportion stating PPMS is considerably higher than what would be expected 6 and suggests, as we found in previous studies, that patients were insecure in their answers regarding the type of disease. We therefore ignore the disease type in our analyses and focus on EDSS levels instead. DMTs were used by 60% of the sample, with usage declining with higher EDSS levels, as expected (Table 1 ) Among users, 24% were on their first DMT treatment; first-generation DMTs were used by 55% of users (Table 2) .
Relapses in the preceding 3 months were reported by 299 patients (16%), of which half occurred in the past month (Table 1) . However, 383 patients (21%) were unsure whether they had a relapse or not, and 85 patients did not answer the question. For these two groups, we assumed that the answer was no. Thus, the mean relapse rate over a 3-month period was estimated at 0.2 (SD = 0.6). Corticosteroids were administered to 131 patients (44%) with relapses, predominantly as infusions (101 patients).
Symptoms and HRQoL
Fatigue and cognitive difficulties were an issue for a majority of patients, and both were related to disease severity ( Figure 2) . Fatigue was present in 95% of the patients, with a mean VAS score of 6.4 (SD = 2.1) for the sample and a score of 5.8, 6.7 and 6.8 for mild, moderate and severe diseases, respectively. Cognitive difficulties were recognised by 72% of all patients (3.5% missing). The mean VAS score in this group was 5.3 (SD = 2.0) overall, 4.7 in the mild, 5.5 in the moderate and 5.9 in the severe group. For the full study sample (assigning 0 to the group with no problems), the mean score was 4.0 (SD = 2.9) and in the mild, moderate and severe groups was 3.4, 4.4 and 4.3, respectively.
The detailed answers to the EQ-5D indicated that both the severity and the domains affected changed with advancing disease. Self-care was unaffected in patients with mild disease, but declined rapidly with advancing disease; mobility, pain and usual activities presented problems for almost all patients already in moderate disease; anxiety/depression was present in over 50% of the patients at all levels ( Figure 3) .
Utility
Utility declined with increasing EDSS (Figure 4) . Mean utility in this specific sample of patients was 0.496 (using the UK tariff) and 0.492 (using the Belgian VAS tariff).
Resource utilisation
Resource utilisation is presented in Table 3 . Hospitalisation was not infrequent in this sample. During the preceding 3 months, 184 patients (10%) were admitted as inpatients. Of these, 149 patients (8%) were admitted to the neurology ward, on average 2.3 (SD = 3.8) times and for a mean of 11.9 (SD = 15.2) days. Admission to a general ward was reported for 50 patients (3%). Day admissions occurred for 318 patients (17%), on average once a month. Inpatient or day admissions to rehabilitation centres occurred for 170 patients (9%). The majority of patients (1637, 88%) had a consultation during the past 3 months, most often with a neurologist (68%), a general practitioner (43%) or a physiotherapist (58%). Investigations and tests were needed by 997 patients (54%) and medications for MS and MS-related symptoms were used by 1623 patients (87%) during the past month. Drugs other than DMTs and corticosteroids were used by 905 (49%) patients, predominantly treatments for walking, spasticity and pain (31%); for depression (15%); and for incontinence (12%). Non-prescription drugs were purchased by 1063 patients (57%).
Investments in equipment and devices to aid patients' mobility were made during the past 12 months for or by 722 patients (39%), most often for modifications to the car or the house, walking aids and wheelchairs.
Community and social services were used by 41% of the patients, most frequently home help and transportation. Help from family was used by 53% of the patients, on average 17.4 days per month and 4.5 hours per day. Both community services and informal care were related to disease severity ( Figure 5 ).
Costs
Total mean annual costs per patient for patients with mild, moderate and severe disease and by EDSS score are presented in Figure 6 and Table 4 . Utility is calculated by relating the scores (1 = no problem; 2 = some problems; 3 = severe problems) of the five domains to a health state valuation system established with the general population using decision analytic methods. The original valuation was produced in the United Kingdom using decision analytic methods (TTO), 14 and a specific Belgian tariff has been developed subsequently, using the EQ-5D VAS rather than TTO. 15, 16 Results using the two tariffs are presented separately as the two methods cannot be compared.
The average cost of a relapse for patients with an EDSS up to 6 was estimated at €2976. All types of costs increased during a relapse, with hospital care representing 34% of the additional cost, informal care 22% and community services 15% (Figure 7 ).
Discussion
This study provides an update to current understanding of the burden of MS on patients, the health care system and society in general in Belgium, based on a cross-sectional survey conducted in 2015.
Within this effort, participation in Belgium was excellent providing one of the largest samples in the study. Partly this may be due to the fact that the survey was distributed by mail, yielding a better response rate than electronic invitations. (A similar phenomenon was observed in the Swedish arm of the study.) More likely, however, the high participation rate was due to the two Belgian patient associations' intense promotion of the study. The sample represents almost perfectly the geographical distribution of the population in the country and is representative in terms of educational level. All levels of disease severity with the exception of the most severe EDSS score exceeded the target participation by far, yielding a very stable analysis across the disease spectrum.
The majority of Belgian patients answered the questionnaire on paper. Compared to online questionnaires where most answers are made compulsory, paper surveys will present with a certain amount of missing data. For most of these, but in particular disease variables and HRQoL, no imputation can be made. Thus, for instance, 5% of Belgian patients did not complete the self-assessed EDSS and had therefore to be excluded from all calculations performed by disease severity groups or by EDSS. They are, however, included in the reporting of resource use in the total sample.
Despite the large participation, it is likely that our study sample is biased towards older patients with more advanced disease and is not representative of prevalence in terms of disease severity in Belgium. Thus, the mean cost per patient in the sample cannot be extrapolated to the total cost of MS in Belgium, nor can it be directly compared to previous studies. It is nevertheless possible to make a number of observations relative to the study performed 10 years ago. The current sample is older and has more severe disease. This is not unexpected as patients in the cross-sectional survey in 2005 were not recruited via the patient association, but in clinical centres where patients have more often highly active disease. 21 DMT usage has thus increased less than what would be expected (from 50% to 60%) as usage is less at higher EDSS levels. On the other hand, the use of services (nurses, home help) has increased considerably, as has its cost.
Overall, the resource utilisation reflects the clinical needs of patients, but they also have to be seen in the light of the organisation of the Belgian health care system, medical traditions and cultural norms. In that respect, it is interesting to note that the utilisation pattern has not changed very much since the 2005 study. Hospital care continues to be frequent, possibly influenced by the advanced disease in this sample, but inpatient admissions have decreased, while day admissions have increased. Consultations are somewhat more frequent in 2015, with a large increase in the proportion of patients that use physiotherapy (from 34% to 58%). This may be only partly explained by the more advanced disease in the 2015 sample. As expected, the use of magnetic resonance imaging (MRI) has increased, from 18% to 34%, as MRIs are firmly included in disease management. Almost all patients in both studies used medication, with similar proportions using prescription drugs other than DMTs (48% and 49%) and purchasing non-prescription drugs (54% and 57%). Interestingly, the use of antidepressants has been reduced (from 25% to 15%).
The mean time to diagnosis in the Belgian sample of this study was slightly under 6 years which is long in view of recent research regarding the benefits of early Intensity of use of informal care (number of days and hours per day during the past month). In all, 55% of the sample use help from the family, but use is clearly concentrated in the severe group: 26% of the patients in the mild, 63% in the moderate and 77% in the severe group rely on family support. DMTs: disease-modifying treatments; EDSS: Expanded Disability Status Scale. Total costs increase with disease severity, but the type of resources changes. Outpatient care and DMTs dominate in early disease, while production losses, informal care, investments and community services dominate in moderate and severe disease.
intervention, 22 but it is also a reflection of the age of the sample that received the diagnosis on average 10 years ago.
In addition to characterising various aspects of the burden of MS on patients and capturing patterns of resource utilisation that could inform future policy DMTs: disease-modifying treatments; EDSS: Expanded Disability Status Scale. Mean 3-month cost of a relapse, estimated as the difference in costs of patients with an EDSS 0-6 with and without a relapse (n = 83 and n = 367, respectively). Patients who were unsure (n = 383, 21% of the sample) or had not answered (n = 85, 5% of the sample) were excluded from the estimation. Invalidity, early retirement and DMT costs are not considered in this calculation as they are unlikely to be affected within 3 months. The average cost of a relapse was estimated to be €2976. The use of all resources increased during a relapse, with hospital care representing 34% of the additional cost, informal care 22% and community services 15%.
recommendations, these data also provide input into cost-effectiveness analyses for reimbursement decisions. The data generated by this study are without doubt the most comprehensive and best available source to describe the HRQoL and resource utilisation patterns of patients with MS in Belgium.
